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The hemodynamlc effects of intravenously administered adeno-
sine, a potent vasodilator, were examined to 15 patients with
pulmonary hypertension . All patients were given adenosine,
50 pagfkg per min, increased by 50 pcg/kg per min a
t 2
min
intervals to a maximum of 500 pgfkg per min or until the
development of untoward side effects. The patients mere than
given oral niredipfne, 20 me every hour, until a m20% decrease in
pulmonary vaswlne resistance o : systentic hypeeentian occurred .
The ndmin:xtrarinn of maximal doses of ndeneslne, 256 x
46 pg/hg per min, produced a 2.4% reduction in pulmonary
artery pressure (p =NS), a37% decrease in pulmonary vascular
resistance (p < 0.001) and a 57% increase in cardiac index (p <
0.001). The administration of maximally effective doses of ntfed-
ipine (91 s 86 mg) produced a 15% reduction in the mean
pulmonary artery pressure (p < 0
.05), a 24% decrease in pulmo .
Adenosine, an intermediate product in the metabolism of
adenosine triphospitate, has been shown to be a potent
vasodilator through actions on specific vascular receptors
(1) . Adenosine produces coronary vasodilation, decreases
systemic vascular resistance and causes relaxation of
smooth muscles, including pulmonary arteries, in vitro (2-
4) . The continuous intravenous administration
of adenosine
to normal healthy subjects has been shown to decrease
systemic vascular resistance and increase pulmonary blood
flow without significant changes in systemic pressure (3)
.
Adenosine is a stable compound with a favorable safety
profile and a very short serum half-lire that makes it a
desirable agent to test vasodilator reserve in pulmonary
hypertension (5). This study was designed to assess the
acute hemodynamie effects of maximally
tolerated do-us oF
adenosine on the pulmonary and systemic circulation in
patients with pulmenar • .
hypertension and to compare these
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nary vascular resistance (p < 0 .01) and an 8%6 increase in cardiac
Index (p a N8) .
There was a significant correlation (r = 0,714, p = 0 .01)
between the reduction in pulmonary vascular resistance that
resulted from adenosine administration and that ochleved waft the
administration of niltedipine
. Six patterns had mhstantiul reduo
lions in pulmonary vascular resistance with adenosine but not
with nifedipine.
Thus, adenosine is an elhctive vasodilator in patients with
pulmonary hypertension and can be used for safe and rapid
assessment of vasodilator reserve in these patients. The ability of
adenosine to reduce pulmonary vascular resistance by 37%, and
its effectiveness In patients In whom offedip(ne was can, suggests
thin the pursuit of an oral mtatogue of adenosine as a therapeulic
agent is warranted .
(JAm Doff Cardful7992;49 ;1060-4y
effects with those of a calcium channel blocking agent also
nitrated to maximal effectiveness (6,7) . In addition, we tested
whether the response to adenosine predicted the response to
calcium channel Hackers .
Methods
Study patients. Fifteen consecutive patients referred to
the University of Illinois Hospital for evaluation of puhtto-
nary hypertension between July 1989 and August 1990 were
enrolled in the study. Eleven patents had primary pulmonary
hypertension
. two had cirrhosis of the liver and two had
collagen vascular disease. The study protocol was reviewed
and approved by the University of Illinois Institutional
Review Board or. January 6, 1989 . The study group com-
prised 13 women and 2 men (mean age 34 ± 10 .5 years). All
patients had a thorough evaluation to identify the cause of
their pulmonary hypertension; the studies included a chest
radiograph, lung scan, pulmonary function testing, echocar-
diography and cardiac catheteri2ation, according to the
protocol of the National Institutes of Health Primary Pulmo-
nary Hypertension Registry (8).
All patients underwent a diagnostic right heart
catheter-
ization, after an overnight fast, to assess hemodynamic
variables. All medicatiuns except digoxin and diuretic agents
were discontinued at least 2 weeks before the study. A 7F
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comport statues after adenosine wilh baseline values and values after nifedipine with values after ]he amend baseline . AD = Met adenosine ; B -
haseline:
B y - second baseline ; N = after nifedipine.
Swan-Dane catheter was placed in the pulmonary artery and
a small Teflon catheter was placed in the femoral artery to
monitor systemic arterial pressures. Cardiac output was
determined by the thermodilution technique . Systemic and
pulmonary artery pressures were measured with values for
pulmonary vascular resistance and systemic vascular resis-
tance was calculated by standard formulas
.
Adenoalae administration, After baseline hemodynamic
measurements were obtained, adenosine was administered
into an anrecabitot vein as a continuous infusion . The
infusion was begun at 50 961kg per thin and increased by
50 dlkg per min every 2 min . The adenosine was titrated to
either a maximal dose of 500 pgll g per min, a reduction in
systemic blood pressure to a mean of 70 mm Hg, >50-bealsf
min increase or decrease in heart rate or the development of
side (Betts. The side
effects included chest pressure or
heaviness, dyspoea . tingling, numbness of the extremities
and nnasea. Once any of these end points was recahed,
hemodynamic measurements were repeated, In a subset of
six patients, pulmonary and systemic pressures and oxygen
saturation in the systemic and pulmonary arteries were
measured at each increase in adenosine dose .
Piifsdipite administration. After adenosine administra-
tion, the patients were transferred to the coronary care unit
where they were acclimated over the next 2 to 4 b . During
this time systemic and pulmonary pressures as well as
cardiac output were measured periodically until stable val-
ues were obtained, and then hourly thereafter . The protocol
for nifedipine administration has been described in detail (7)
.
Briefly, nifedipine, 20
mg every hour, was administered until
one of the following occurred : a a255% reduction in pulmo-
nary vascular resistance that did not decrease further with
SclOrAtSlin FT AL
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additional dosing, systemic hypotension, a total dose
of
200
mg
of nifedipine or intolerable adverse effects that
required discontinuation of
the drug .
Statistical mellmda
. The mean values t SD were com-
puted for all variables measured . Comparisons between
control and treated states were made with a Student r test for
unpaired data . A one-way analysis of variance was used to
compare the two drug effects The Pearson product correla-
tion coefficient was used to examine the differences;between
the two treatments .
Results
Baseline hemadyn>mk (fables 1 and 21. AB 15
patients included in the study had pulmonary hypertension
manifested by markedly elevated mean pulmonary artery
pressure (56 ± 16 mm fig)
and pulmonary vascular msis-
tance (14
± 711)
as well as a reduced cardiac index (2 '_ 0 .6
literslmin per m2).
Adenosineeffects(Tablesland2). Adenosine dosing was
limited by the occurrence of drug-induced side effects in
each case. The administration of
maximal doses of adeno-
sine
(256 ±
46
4g&&
per min, range 200 to 350) resulted in a
2 .4% reduction in mean pulmonary artery pressure (p = NS)
and a 37% decrease in pulmonary vascular resistance (p <
0 .001). Adenosine increased cardiac index
by 57% (p <
0 .001)
and increased heart rate by 13% (84 to 94 beats/min)
(p < 0.05), resulting in an ircrease of 35% in the stroke
volume index (26 to 35 offbeat per m2 ) (p < 0 .01). In
addition, systemic vascular resistance decreased
by 40%
(p < 0 .001), whereas systolic blood pressure decreased by
only
6 .8%
(p < 0.01)
.
Adenosine also resulted in a
4%
Table 1 . Hcrnudynamic Effects
of
Adenosine and Nifedipine in 15 Patients With Pulmonary Hypeatersion
Sitar P.1--y Artery Pressure (mm (15) Card= Ompm drte,vmlnl Pubnenary Vasralar Resistance Ill)
RNo
. B AD B, N 13 AD B_
N B AD B,
N
I 60 62 66 64 2 .37 3.01 2.14 2,45 22.4 17.9 25 .6 21.6
28 3R 29 19 5 .72 8 .43 n49 633 42 3
.44
354 4 .26
3 75 76 90 62 26
4.04 2
.58 3
.56
26 17
32 16
4 to 71
66
75
304 3 .78 3 .11 1468 23.4 15 .1 19.3 16 .5
5 80 8o 95
%1 3.28 409 3 .8 3.3 20 .7 15,9 25,9
22 .1
6
51 41
69 34
3 .72 106 5 .24 4.57 11 .8 396 11 .8 6.3
7 62 67 67 62 3 .61
4.14
251
293 141 13 22.7 19.4
8 53 44 43 30
4.7 936 603 663 10.2 3.2 68 39
9 55 50 58 57
4 .73
623 i09 5.95 9.9
6.4 9.6 7'
18 65 60 45 42 3 .56 6.25 2.64 1 .2 13.7 8.5 11,4 8 1 €
11 45 48 13 % 3.27 5 .85 5 3,15 11 .3
7?3 12 .4 13 .6
12
411 45 43 42 336 6 .62 3 . 23 5 .6 10 .4 5 .4 11,4 8.1
13 9 ;5 43 54 53 5 .45
'
A87 7.22 72 5 .6 7,5 5.4
14 63 65 59 61 3 .39 4.3 3.56 3.96 16.5 13.7 14.6 13.1
15 35 30 48 30 4.3 8.3 5.21 4,17 7,2
2.9 7,5
4.8
Mean 56.13 54 .73 60,3 51.53 3 .8 5.96
4.15 4.52 14_1 9.24 IS 11.39
SD 15.54 15 .14 17.82 16 .15 0 .98 1 .45 1.48
656 5.59
8.31
641
P.
NS - <0 .05 - <0 .001 - NS -
<9985 -
10
.01
1 062
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Table 2 . Henludynarnic Effects of Adenosine and Nifedipine in 15 Palients With Pulmonary Hypertension
P value enmaa7sens and aob-iarians in Figure 1 .
increase in systemic oxygen saturation, a 27% increase in
systemic 1'o x and a 22% increase in putmonay oxygen
saturation (p < 0.0001) .
The reported side effects were
shortness of breath (n = 7),
abdominal discomfort or nausea (n = 6), chest pressure (n =
4), headache (n = 3) and numbness or tingling of the
extremities (n -
3). Some of the patients experienced more
than one side effect
. All side effects abated within 30 s of the
discontinuation of the adenosine infusion . No adverse effect
was prolonged; therefore, no patient's hospital stay was
extended because of adenosine administraliun . No arrhyth-
mias were noted during any adenosine infusion,
To examine the possibility that tutoring
the adenosine to
the onset of side effects might overshoot the
maximal
pharmacotogtc effect, a subset of six patients had systemic
and pulmonary artery pressures and oxygen saturation re-
corded at each dosing
i ncrement. in all six patients the
arlerievenous oxygen saturation difference usrrowed with
each dose increment, reflecting an increased cardiac output
with each successive dose . In all six patients, pulmonary
vascular resistance either remained the same or decreased
with successivc doses .
Nifedipine effects (Tables I and 2)
. The administration of
maximally effective doses of nifedipine (91 ± 36 mg, range 40
10160) resulted in a 15% reduction in mean pulmonary artery
pressure (p < 0
.05) and a 24% decrease in pulmonary
vascular resistance (p < 0 .01) . Nifedipinc increased cardiac
index by 8% (p = NS) and heart rate by 11% (p = NS),
resulting in a slight 8% increase in stroke volume index from
26 ± 13 to 28 m 13
mllbeat per m2 (p = NS). Nifedipine also
caused systemic vascular resistance to decrease by 23%
(P = NSI and systolic blood pressure to decrease by 14%
(p < 0 .05) .
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Side elects that limited nifedipine dosing
incladed, sys-
temic Ityputension (two patients), severe nausea and vomit-
ing (one patient) and lack of further hemodynamic effect on
pulmonary resistance with the next dose (seven patients) .
Three patients who did not have a 20% reduction in
pulmonary vascular resistance with adenosine also did not
respond to nifedipine. However, six patients who did not
respond to nifedipine responded to adenosine with a 34% to
48% decrease in pulmonary vascular resistance . In addition,
two patients who had limited tolerance to nifedipine because
of systemic hypotension had a decrease in pulmonary vas-
cular resistance with adenosine of 23% and 44%, respec-
tively.
Comparative efeds of adenosine and nlf6dipien
. Nife-
dipine resulted in a 13% reduction in pulmonary
artery
pressure in contrast to a t% decrease with adenosine (p =
NS) . Cardiac output increased
by 5690 with adenosine ver
rus 18% with nifedipine (p < u .05) . Thus,
adeuosine resulted
in a greater decrease in pulmonary vascular resistance (37%)
than did nifedipine (24%) (p < 0
.00011. (pig. I). The reduc-
tion in pulmonary vascular resistance induced by adenosine
was associated primarily with an increase in cardiac output,
whereas that induced by nifedipine was associated with both
a decrease in pulmonary artery pressure and an increase in
sardine output
. There was a significant correlation (r =
0.714, p - 0.01) between the reduction in pulmonary vascu-
lar resistance that resulted from adenosine administration
with that achieved with nifedipine (Fig, 2). There was no
correlation between the increase in cardiac index (r = -0
.20.
p = NS) or the reduction in pulmonary artery pressure (r =
0
.476, p = NS) achieved with adenosine and that achieved
with nifedipine. It is unlikely that these drug effects would
have been altered by administration of these agents in
Pubronary Capillary Wedge
Pressure Imm Hgl
Right Afflol Pressure
on . Hg)
Systemic Systolic Pressure
(mm Hg) heist tale Ibeatslmirl
Pt No. a AD B, N B AD B, N B AD B, N
B AD & N
I
7B61;151914 Is 100 105 106 81 94 90 96 102
9 4 9 6 2 I 4 4
I
108 98 98 103
74 9B 74 74
7 8 6 6 13 n 7 7 bas 101 75e4
110
10 0x 101
4 9 13 6 9 I 12 9 8 132 116 113 99
67 77
e1 96
5 12 15 13 B 15 15 B 8 118 101 84 93 Itt 102 104 108
6 9 3 7 5 4 5 7 4 104 94 90 77 66 96 78
81
7 10 11 7 5 19 25 16 15 1m 100 96 87 S4 90
95 8B
A 7 D 10 4 4 10 3
3
95 84
100
89 72
10B 92
87
9 s 10 10 I I 10 12
7
8
80 68 83
70 78
79 84 84
l0 9 7 9 6 9 S 8
95
Id
93 64 15 92 99 III
It 8 5 11 11 13, 109 97 117 76 sa 'm 102 85
12 6 9 7 5 7 11 5 115 117 98 74 56 77 67 77
13 9
A - 6 3 5 I 107 97 93 65 76 90 77 Ion
14 7 7 - 8
19 24 16 96 97 89 75 112 118 II6 118
IS 4 6 6 10 2 5 6 4
81 66 86
8I
Aa 110 1W 69
Mean 7.73 9.6 e5 7 .4 8 .2 1147 833 7 .47
103 96 95 81 A4 94 91 92
AD 2.12 8.07 2.27 3 .54 66 676 4-4
5 .48 13 14 11 11 15 12 14 14
p - 5.1)1 - NS - 0 .00l - Ns - 0.o! - 0.05 - 0 .69 -
Ns
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Figure 1
. Selective effects of adenosine and nifedipine on mean
pmmnnary artery pressure (PAP), cardiac output ([ :U) and puteo-
nary vascular residence IPVR) .It appears that the two agents lower
pulmonary vascular resistance by slightly different mechanisms .
random order occaasc the ultashort half-life (8 s) of adeno-
sine makes any residual adenosine effect unlikely .
Discussion
Adenosine for testing in pulmonary hyperension, Adeno-
sine is
an
endogenous nucleoside that has a variety of
pharmacologic effects, including modulation of platelet func-
tion and vasodilation (2,3,9) . The vasodilator effects ;rave
been examined in various vascular beds in normal volunteers
(2-4,10)
. Adenosine administration produces a stepwise
increase in coronary blood flow with increasing incremental
dosing (2) . Bush et al . (3) reported that adenosine infusion
at a constant dose of 70 pg/kg per min resulted in an in-
crease in pulmonary blood flow of 0
.52
.+ 6
.08 mini m - '-
and a decrease in systemic vascular resistance of 357
44 dynes •s •c
m s without inducing reflex tachycardia . These
effects, coupled with the short half-life of adenosine, are
desirable properties for a vasodilator for testing in pulmo-
Figure 2
. Comparison of the percent change in pulmonary vascular
resistance (PVR) with adenosine and with nifedipine
. Generally,
adenosine caused a larger reduction than did nifedipine in the same
patient.
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nary hypertension. The mechanism that produces these
effects is considered to be secondary to stimulation of
endothelial cell and vascular smooth muscle receptors of the
A, type, which induce vascular smooth muscle relaxation by
increasing cyclic adenosine monophosphate (1).
The aaailabitiry of a safe, easily administered test drug for
rapid determination of pulmonary vasoreactivity would be a
valuable investigative adjunct . Adenosine can induce hemo-
dynamic changes within seconds and can be eliminated,
along with untoward side effet:ls, in seconds. The ideal
predictive agent would induce a hemodynamic response that
would correlate with the response to oral vasodilators such
as calcium antagonists. Proslacyclin has been used as an
acute testing agent, but maximal effectiveness is almost
always limited by systemic hyportnsion . The response to
pr[IstacyclmL however . appears to predict the response to
calcium channel blockers(11-13) .
In the present
study. adenosine decreased pulmonary
vascular resistance by >20% in 12 o€15 patients tested
. The
three patients who did not respond to adenosine also did not
respond to nifedipine- There were six patients who did net
respond to nifedipine although they responded to adenosine,
and two patients tad
limited tolerance to nifedipine because
of hypotension, whereas they had a decrease in pulmonary
vascular resistance of 23% and 46%, respectively . These
findings suggest that adenosine has broader vasodilator
abilities than does nifedipine in pulmonary hypertension,
and that perhaps other classes of drugs should be tested in
patients who respond to adenosine but not nifedipine. Be-
cause no patient treated with adenosine had systemic hypo-
tension, even though
pulmonary vascular resistance was
reduced, and because the effects of adenosine can be as-
sessed in minutes during the catheterization procedure, this
drug is a very attractive test agent. The testinv of the
maximal physiologic effectiveness of the calcium channel
blockers requires invasive hemodynamie monitoring for a
period of hours .
Mechanism of drug uboh . Adenosine and nifedipine
appear to cause vasodilation by different mechanisms, as
exemplified by their differing hemodynamic effects. Adeno-
sine improves hemodynamie status primarily by increasing
cardiac output and decreasing pulmonary vascular resis-
tance. This overall increase in cardiac output would account
for the increase in the pulmonary capillary wedge pressure
and right atria] pressure due to adenosine . Nifedipine admin-
istration resulted in a nonsignificant increase in cardiac
output ; hence, it had no significant effect on pulmonary
capillary wedge pressure or right atrial pressure . However, it
did cause a significant reduction in pulmonary artery pres-
et . These two drugs may produce mildly disparate hemo-
dynamic responses, but adenosine is used to predict vasodi-
lator reserve in these patients .
Our study was of a limited scope . Because of the method
of preparation and dosing schedule used, we were unable to
assess the effects of a long-term adenosine infusion
. We also
did nut identify the cellular mechanisms responsible for the
106 4
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hemodynamic effects of
adenosine, although they appear t0
differ from
those of the calcium channel blockers .
Conclusions. Adenosine is en effective vasodilator in
patients with pulmonary hypertension and can be used safely
to quickly to assess vasodilator reserve in these patients . It
appears to decrease pulmonary vascular resistance primarily
by increasing cardiac output . The observation that adeno-
sine was able to reduce pulmonary vascular resistance by
37% on average, and that it was effective in patients in wham
nifedipine was not, suggests that the parsuiJ of oral ana-
logues of adenosine as possible therapeutic agents for the
treatment of pulmonary hypertension is warranted.
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